LADENBURG THALM/SH SH started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $14.00 price target on the biotechnology company’s stock. LADENBURG THALM/SH SH’s price objective indicates a potential upside of 273.33% from the stock’s current price.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Tuesday, August 14th. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 13th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $11.00 price target on shares of Aptevo Therapeutics in a report on Friday, August 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Aptevo Therapeutics presently has an average rating of “Buy” and an average price target of $10.69.
Shares of NASDAQ APVO opened at $3.75 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.50. The stock has a market capitalization of $82.29 million, a price-to-earnings ratio of -2.45 and a beta of 2.27. Aptevo Therapeutics has a fifty-two week low of $2.54 and a fifty-two week high of $6.35.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.07. The business had revenue of $6.83 million during the quarter, compared to the consensus estimate of $4.17 million. Aptevo Therapeutics had a negative return on equity of 45.53% and a net margin of 74.01%. On average, equities analysts anticipate that Aptevo Therapeutics will post -2.41 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of Aptevo Therapeutics by 53.3% during the second quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock worth $5,736,000 after purchasing an additional 399,400 shares during the period. EAM Investors LLC acquired a new stake in shares of Aptevo Therapeutics during the second quarter worth about $552,000. Dimensional Fund Advisors LP lifted its holdings in shares of Aptevo Therapeutics by 10.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,351,656 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 131,804 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Aptevo Therapeutics by 346.6% during the first quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock worth $832,000 after purchasing an additional 197,341 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aptevo Therapeutics during the second quarter worth about $148,000. 33.09% of the stock is owned by institutional investors and hedge funds.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.